| Gentiva Hospice 550 Fannin Street Suite 1230, Beaumont, TX, 77701 | |
| (409) 924-0085 |
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| Name | Gentiva Hospice |
|---|---|
| Location | 550 Fannin Street Suite 1230, Beaumont, Texas |
| Hospice ID | 451638 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 700 |
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| NPI Number | 1669844288 |
| Organization Name | Gentiva Healthcare |
| Address | 8050 Eastex Fwy Beaumont, Texas, 77708 |
| Phone Number | (409)924-0085 |
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| NPI Number | 1821099714 |
| Organization Name | Odyssey Healthcare Operating A, Lp |
| Address | 8050 Eastex Fwy Beaumont, Texas, 77708 |
| Phone Number | (409)924-0085 |
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 98.4 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 98.4 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 93.1 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.7 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.5 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 98.6 | 93.3 |
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| Home Health Aides | 35 |
| Licensed Practical or Vocational Nurses | 10 |
| Medical Social Workers | 10 |
| Registered Nurses | 52 |
| Other Personnel | 16 |
| Total Employees | 123 |
|---|
News Archive
A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.
Addicts, even those who have been abstinent for long periods of time, are often still vulnerable to their own memories of prior drug use.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.
› Verified 7 days ago
| Altus Hospice Of Beaumont Lp Location: 3180 College Street, Beaumont, Texas, 77701 Phone: (409) 924-0085 |
| Gentiva Hospice Location: 550 Fannin Street Suite 1230, Beaumont, Texas, 77701 Phone: (409) 924-0085 |
| New Century Hospice Of Beaumont Location: 2615 Calder St. Ste. 660, Beaumont, Texas, 77702 Phone: (409) 924-0085 |
| Professional Health Care Location: 2533 Calder, Beaumont, Texas, 77702 Phone: (409) 924-0085 |